S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:AXGN

AxoGen (AXGN) Competitors

$8.89
-0.02 (-0.22%)
(As of 05/26/2023 ET)
Compare
Today's Range
$8.77
▼
$9.06
50-Day Range
$8.48
▼
$10.38
52-Week Range
$7.20
▼
$13.66
Volume
80,943 shs
Average Volume
191,608 shs
Market Capitalization
$380.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

AXGN vs. EDAP, ZYXI, VRAY, FONR, BSGM, ELMD, HYPR, BLFS, OM, and BLUE

Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Zynex (ZYXI), ViewRay (VRAY), FONAR (FONR), BioSig Technologies (BSGM), Electromed (ELMD), Hyperfine (HYPR), BioLife Solutions (BLFS), Outset Medical (OM), and bluebird bio (BLUE). These companies are all part of the "medical" sector.

AxoGen vs.

Edap Tms (NASDAQ:EDAP) and AxoGen (NASDAQ:AXGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.

Edap Tms has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Edap Tms presently has a consensus price target of $13.75, suggesting a potential upside of 36.00%. AxoGen has a consensus price target of $17.00, suggesting a potential upside of 91.23%. Given AxoGen's higher possible upside, analysts plainly believe AxoGen is more favorable than Edap Tms.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edap Tms
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
AxoGen
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

48.8% of Edap Tms shares are owned by institutional investors. Comparatively, 76.2% of AxoGen shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by insiders. Comparatively, 7.5% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AxoGen has a net margin of -17.01% compared to Edap Tms' net margin of -19.22%. AxoGen's return on equity of -15.23% beat Edap Tms' return on equity.

Company Net Margins Return on Equity Return on Assets
Edap Tms -19.22% -16.56% -11.31%
AxoGen -17.01% -15.23% -7.88%

AxoGen received 92 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.77% of users gave AxoGen an outperform vote while only 63.50% of users gave Edap Tms an outperform vote.

CompanyUnderperformOutperform
Edap TmsOutperform Votes
341
63.50%
Underperform Votes
196
36.50%
AxoGenOutperform Votes
433
72.77%
Underperform Votes
162
27.23%

In the previous week, Edap Tms had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Edap Tms and 3 mentions for AxoGen. AxoGen's average media sentiment score of 1.15 beat Edap Tms' score of 0.62 indicating that AxoGen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edap Tms
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AxoGen
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edap Tms has higher earnings, but lower revenue than AxoGen. Edap Tms is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$57.97 million6.44-$3.09 million-$0.30-33.70
AxoGen$138.58 million2.75-$28.95 million-$0.58-15.33

Summary

AxoGen beats Edap Tms on 12 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXGN vs. The Competition

Export to Excel
MetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$380.49M$3.36B$4.56B$6.18B
Dividend YieldN/A1.59%2.32%6.15%
P/E Ratio-15.336.7470.4011.24
Price / Sales2.7567.143,695.1886.22
Price / CashN/A14.2397.53107.27
Price / Book3.904.565.037.13
Net Income-$28.95M$116.63M$118.58M$192.91M
7 Day Performance-4.10%-0.82%1.09%0.20%
1 Month Performance-1.44%-3.79%1.28%1.33%
1 Year Performance-8.54%10.48%19.51%-0.24%

AxoGen Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDAP
Edap Tms
1.9549 of 5 stars		$9.99
-3.6%		$13.75
+37.6%		+42.4%$368.73M$57.97M-33.30223Short Interest ↑
High Trading Volume
ZYXI
Zynex
2.4097 of 5 stars		$9.67
-0.9%		$19.63
+102.9%		+24.3%$354.41M$158.17M21.49774
VRAY
ViewRay
2.5223 of 5 stars		$0.58
-7.9%		$3.18
+448.0%		-83.3%$116.11M$105.86M-0.97267
FONR
FONAR
0 of 5 stars		$17.46
+0.6%		N/A+6.2%$114.19M$97.59M0.00495Upcoming Earnings
Short Interest ↑
BSGM
BioSig Technologies
2.0984 of 5 stars		$1.42
+1.4%		$3.50
+146.5%		+24.6%$100.10M$290,000.000.0049Gap Up
ELMD
Electromed
0 of 5 stars		$11.68
-2.8%		N/AN/A$99.98M$41.66M41.71N/A
HYPR
Hyperfine
2.3634 of 5 stars		$1.40
+2.9%		$3.97
+183.3%		-45.8%$99.51M$6.81M-1.59186Gap Up
BLFS
BioLife Solutions
1.7529 of 5 stars		$22.26
+0.1%		$28.00
+25.8%		+52.7%$967.42M$161.76M-6.53432Insider Buying
News Coverage
OM
Outset Medical
1.3711 of 5 stars		$20.20
-8.6%		$24.50
+21.3%		-5.7%$994.45M$115.38M-5.72444
BLUE
bluebird bio
2.2586 of 5 stars		$3.70
-1.1%		$6.67
+80.2%		+8.5%$393.72M$3.60M-2.16518

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:AXGN) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -